nor-Binaltorphimine dihydrochloride
(Synonyms: nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride) 目录号 : GC13645
nor-Binaltorphimine dihydrochloride是一种有效的选择性κ阿片受体(KOR)拮抗剂。
Cas No.:113158-34-2
Sample solution is provided at 25 µL, 10mM.
nor-Binaltorphimine dihydrochloride is a potent and selective κ opioid receptor (KOR) antagonist[1]. nor-Binaltorphimine dihydrochloride can block the binding of endogenous ligands to KOR, thereby regulating pain perception, emotions and addictive behaviors[2, 3]. nor-Binaltorphimine dihydrochloride can reduce morphine withdrawal symptoms and the resulting conditioned place aversion in rats[4].
In vitro, treatment of rat pheochromocytoma cell line PC12 cells with nor-Binaltorphimine dihydrochloride (100nM) for 10min reversed the inhibitory effect of U-69593 (κ-opioid receptor agonist) on nicotine-induced increase in tyrosine hydroxylase (TH) enzyme activity and TH mRNA level[5].
In vivo, nor-Binaltorphimine dihydrochloride (2mg/kg) was intraperitoneally injected into hyperlipidemia model mice, blocking the normalizing effect of U50488H on mouse endothelial ultrastructure and function, inhibiting U50488H-induced increase in Akt/eNOS phosphorylation, increase in serum/medium NO levels and enhancement of eNOS activity, and also blocking the inhibitory effect of U50488H on iNOS activity[6].
References:
[1] Schmidhammer H, Erli F, Guerrieri E, et al. Development of diphenethylamines as selective kappa opioid receptor ligands and their pharmacological activities[J]. Molecules, 2020, 25(21): 5092.
[2] Ji M J, Yang J, Gao Z Q, et al. The role of the kappa opioid system in comorbid pain and psychiatric disorders: function and implications[J]. Frontiers in Neuroscience, 2021, 15: 642493.
[3] Kishioka S, Kiguchi N, Kobayashi Y, et al. Pharmacokinetic evidence for the long-lasting effect of nor-binaltorphimine, a potent kappa opioid receptor antagonist, in mice[J]. Neuroscience letters, 2013, 552: 98-102.
[4] Kaski S W, White A N, Gross J D, et al. Potential for kappa-opioid receptor agonists to engineer nonaddictive analgesics: a narrative review[J]. Anesthesia & Analgesia, 2021, 132(2): 406-419.
[5] Takekoshi K, Ishii K, Kawakami Y, et al. κ-Opioid inhibits catecholamine biosynthesis in PC12 rat pheochromocytoma cell[J]. FEBS letters, 2000, 477(3): 273-277.
[6] Tian F, Zheng X Y, Li J, et al. κ-Opioid receptor stimulation improves endothelial function via Akt-stimulated NO production in hyperlipidemic rats[J]. Scientific reports, 2016, 6(1): 26807.
nor-Binaltorphimine dihydrochloride是一种有效的选择性κ阿片受体(KOR)拮抗剂[1]。nor-Binaltorphimine dihydrochloride能够阻断内源性配体与KOR的结合,从而调控疼痛感知、情绪及成瘾行为[2, 3]。nor-Binaltorphimine dihydrochloride能够降低大鼠的吗啡戒断症状以及随之而来的条件性位置厌恶[4]。
在体外,nor-Binaltorphimine dihydrochloride(100nM)处理大鼠嗜铬细胞瘤细胞系PC12细胞10min,逆转了U-69593( κ-阿片受体激动剂)对尼古丁诱导的酪氨酸羟化酶(TH)酶活性增加和TH mRNA水平升高的抑制作用[5]。
在体内,nor-Binaltorphimine dihydrochloride(2mg/kg)通过腹腔注射治疗高脂血症模型小鼠,阻断了U50488H对小鼠内皮超微结构和功能的正常化作用,抑制了U50488H诱导的Akt/eNOS磷酸化增加、血清/培养基NO水平升高以及eNOS活性的增强,还阻断了U50488H对iNOS活性的抑制作用[6]。
Cell experiment [1]: | |
Cell lines | PC12 cells |
Preparation Method | Experiments were initiated by replacing the medium with HEPES-buffered Krebs buffer containing various concentrations (10nM–1μM) of U-69593 or U-69593 (1μM) in the presence of nor-Binaltorphimine dihydrochloride (100nM), and the cells were incubated at 37°C for 10min. Then, cells were homogenized in 0.25M sucrose (50 volumes) using a glass tissue grinder, measurement of tyrosine hydroxylase (TH, a rate-limiting enzyme in biosynthesis of catecholamine) enzyme activity. |
Reaction Conditions | 100nM; 10min |
Applications | Nor-Binaltorphimine dihydrochloride reverses the inhibitory effect of U-69593 (a κ-opioid receptor agonist) on nicotine-induced increases in tyrosine hydroxylase (TH) enzyme activity. |
Animal experiment [2]: | |
Animal models | Sprague Dawley rats |
Preparation Method | Sixty male 8-weekold Sprague Dawley rats were randomly divided into six groups: normal diet group (ND), high-fat diet group (HFD), high-fat diet+saline group (HFD+V) (0.3mL saline was intraperitoneally (i.p.) injected every 2 days), high-fat diet+U50488H group (HFD+U) (1.25mg/kg U50488H was i.p. injected every other day), high-fat diet+nor-Binaltorphimine dihydrochloride group (HFD+N) (2.0mg/kg nor-Binaltorphimine dihydrochloride, was i.p. injected every other day), high-fat diet+U50488H+nor-BNI group (HFD+U+N) (2.0mg/kg nor-Binaltorphimine dihydrochloride was i.p. injected and 1.25mg/kg U50488H was i.p. injected 10min later every other day). ND group received a regular chow diet and all other groups received a high-fat (5% cholesterol supplemented) diet. |
Dosage form | 2mg/kg; i.p. |
Applications | Nor-Binaltorphimine dihydrochloride blocked the normalizing effects of U50488H on endothelial ultrastructure and function under hyperlipidemic conditions. nor-Binaltorphimine dihydrochloride inhibited the U50488H-induced increase in Akt/eNOS phosphorylation, serum/medium NO levels, and enhanced eNOS activity. In addition, nor-Binaltorphimine dihydrochloride blocked the inhibitory effect of U50488H on iNOS activity. |
References: |
Cas No. | 113158-34-2 | SDF | |
别名 | nor-Binaltorphimine dihydrochloride; nor-BNI dihydrochloride | ||
化学名 | (4bS,8R,8aS,10aS,11R,14aS,19aR,20bR)-7,12-bis(cyclopropylmethyl)-6,7,8,8a,9,10,10a,11,12,13,14,19a,20,20b-tetradecahydro-5H-4,8:11,15-dimethanodibenzofuro[2,3-a:3',2'-i]dipyrido[4,3-b:3',4'-h]carbazole-1,8a,10a,18-tetraol dihydrochloride | ||
Canonical SMILES | OC1=C(O2)C3=C(C[C@]4([H])[C@]5(O)CC(C(C[C@@]6(O)[C@@]7([H])CC8=C9C(O%10)=C(O)C=C8)=C%11[C@@]%10([H])[C@@]69CCN7CC%12CC%12)=C(N%11)[C@@]2([H])[C@]35CCN4CC%13CC%13)C=C1.Cl.Cl | ||
分子式 | C40H43N3O6.2HCl | 分子量 | 734.72 |
溶解度 | <18.37mg/ml in Water; <18.37mg/ml in DMSO | 储存条件 | 4°C, sealed storage, away from moisture |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
![]() |
1 mg | 5 mg | 10 mg |
1 mM | 1.3611 mL | 6.8053 mL | 13.6106 mL |
5 mM | 0.2722 mL | 1.3611 mL | 2.7221 mL |
10 mM | 0.1361 mL | 0.6805 mL | 1.3611 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet